Home › Compare › IPLDP vs ABBV
IPLDP yields 44.62% · ABBV yields 3.12%● Live data
📍 IPLDP pulled ahead of the other in Year 1
Combined, IPLDP + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IPLDP + ABBV for your $10,000?
Interstate Power and Light Company, a public utility company, generates and distributes electricity, and distributes and transports natural gas to retail customers in Iowa. The company operates through three segments: Electric Operations, Gas Operations, and Other. It generates electricity from coal, natural gas, and wind energy; and purchases electricity from wholesale energy markets. The company also sells electricity to wholesale customers, including municipalities and rural electric cooperatives in Minnesota, Illinois, and Iowa. In addition, it generates and distributes steam for customers in Cedar Rapids, Iowa; and owns overhead electric distribution lines, underground electric distribution cables, and substation distribution transformers, as well as gas mains in Iowa. The company provides utility services to incorporated communities. It offers electric utility services to retail customers in various industries, such as farming, agriculture, industrial manufacturing, chemical, packaging, and food industries, as well as gas utility services for various industries comprising research, education, hospitality, manufacturing, and chemicals. As of December 31, 2020, it supplied electric service to approximately 495,000 retail customers and natural gas service to approximately 225,000 retail customers. The company was formerly known as Iowa Railway and Light Corporation. The company was incorporated in 1925 and is based in Cedar Rapids, Iowa. Interstate Power and Light Company operates as a subsidiary of Alliant Energy Corporation.
Full IPLDP Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.